Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®

Pre-planned primary outcome analysis continues to show clinically significant improvement in invasive disease-free survival as data mature for people with HR+, HER2- high risk early breast cancer New data presented includes an additional 3.6 months of follow-up and more than 1400 patients